MCL Literature Feed

This review details diverse BTKi resistance mechanisms beyond BTK mutations, providing a framework for developing next-generation inhibitors and combination strategies to overcome treatment failure in MCL.

Single-cell RNA sequencing reveals pre-existing, minor therapy-resistant subclones at diagnosis, which are selected during treatment, explaining early relapse and highlighting cell-cycle dysregulation as a common resistance mechanism.

Single-cell multi-omics reveals genetic and non-genetic pirtobrutinib resistance mechanisms in MCL, identifying the cohesin complex as a potential target to restore drug sensitivity.

This case report identifies a rare, aggressive MCL variant with blastoid morphology, TdT expression, and MYC rearrangement, broadening the known clinicopathological spectrum and posing significant diagnostic challenges.

A real-world, retrospective study demonstrates that clinical next-generation sequencing panels provide significant prognostic and predictive data in mantle cell lymphoma, aiding in the optimization of patient management.

Genomic analysis reveals MCL relapse is driven by the expansion of pre-existing resistant subclones, not new mutations, highlighting the need for deep sequencing at diagnosis to prevent recurrence.

Preclinical data suggests PRMT5 inhibition is a promising combination therapy strategy for high-risk MCL with ATM and TP53 mutations, which are known to confer therapeutic resistance.

This comprehensive review synthesizes emerging biomarkers beyond standard prognosticators, including MRD, ctDNA, and advanced imaging, to better guide personalized treatment in the targeted therapy era.

This study identifies the SOX11-UHRF1 axis as a new therapeutic target in MCL, demonstrating that the UHRF1 inhibitor CM272 effectively suppresses tumor growth in preclinical models.

A novel single-cell technique, LiP-Seq, identified IFITM2 upregulation in rare persistent MCL cells post-CAR-T, revealing a new mechanism of immune evasion and a potential therapeutic target.

Absence of CD38 expression in conventional nodal MCL strongly correlates with TP53 inactivation and a distinct genetic profile, identifying a high-risk subgroup via routine flow cytometry.

A family history of hematological malignancy is associated with inferior event-free survival in mantle cell lymphoma, suggesting it may be a novel adverse prognostic factor.

Preclinical data shows that inhibiting the cell cycle regulator CDC20 suppresses MCL growth by downregulating the PI3K/AKT pathway, identifying CDC20 as a novel therapeutic target.

This first comprehensive proteogenomic analysis of MCL demonstrates that integrating protein data with genomics improves survival prediction and identifies molecular subtypes linked to IGHV/CCND1 mutations, offering new prognostic tools.

A novel liquid biopsy technique using cell-free chromatin profiling non-invasively tracks disease origin and monitors therapy response, offering a powerful new tool for MRD and biomarker discovery.

Proteomic profiling identified an MCL-specific protein signature, including seven targets missed by RNA analysis, offering novel avenues for CAR-T therapy and personalized treatment.

A distinct DNA demethylation signature in MCL tumors acts as a "fossil record" of early gene activation, offering a novel bioinformatic approach to understand the cancer's developmental origins.

This review summarizes how epigenetic dysregulation drives MCL pathogenesis, highlighting the potential for novel biomarkers and therapeutic targets based on mechanisms like DNA methylation and histone modification.

A new preclinical cell line and patient-derived xenograft model of a non-MCL lymphoma with a CCND1 rearrangement provides a tool to study the specific biological role of this key driver.

This longitudinal study reveals MCL acquires new high-risk genetic features after chemoimmunotherapy, explaining relapse and emphasizing the need for genomic profiling to guide subsequent therapies.

This report summarizes the 2025 LRF MCL Workshop, highlighting key research developments in pathogenesis, resistance, and novel therapies, thereby setting the agenda for future clinical and translational research.

High expression of the lncRNA MALAT1 is a novel, independent biomarker for favorable prognosis in MCL, inversely correlating with proliferation signatures and EZH2 activity.

This bioinformatic study identified a prognostic network of six circular RNAs in mantle cell lymphoma that regulate key pathways like BCR signaling, suggesting their potential as novel biomarkers.

This review outlines the historical evolution in understanding transformed mantle cell lymphoma, highlighting changes in its pathological diagnosis, genomic drivers, and the clinical challenges it presents.

This study demonstrates that TP53 mutation heterogeneity, not just presence, defines distinct prognostic subgroups in MCL, enabling more precise risk stratification beyond a simple binary classification.

Long-read sequencing systematically identifies novel fusion transcripts in MCL, potentially revealing new prognostic biomarkers and therapeutic targets beyond the canonical t(11;14) translocation.

Mendelian randomization provides genetic evidence that obesity is a causal risk factor for developing mantle cell lymphoma, identifying a potentially modifiable risk factor for the disease.

In the phase 3 TRIANGLE trial for young, fit MCL, adding ibrutinib to induction immunochemotherapy improves failure-free survival, with noninvasive genotyping confirming its efficacy and treatment dynamics.

A new genomic model integrating mutations (e.g., TP53) and copy number variations improves risk stratification for elderly, newly diagnosed MCL patients treated with chemoimmunotherapy.

In the MCL0208 trial for young patients, IGHV mutation status and stereotyped receptors predicted outcomes after intensive chemoimmunotherapy and transplant, offering a new biomarker for frontline risk stratification.